Enhance your patent search with AI. Try the FREE AI-powered tool

Smart(er) healthcare through AI-driven biomarker analysis

ai healthcare biomarker

Artificial intelligence is transforming healthcare through groundbreaking technologies in diagnostics and patient care. Ellipsis Health’s speech-based AI system offers real-time mental health insights, while 4bases’ cfDNA biomarker detection enhances early identification of organ transplant rejection. These innovations exemplify the potential of AI to improve diagnostic accuracy and patient care across diverse medical fields.   CFDNA […]

Cancer remains leading focus for gene therapy innovation

gene therapy for cancer

Gene therapy is revolutionizing cancer treatment, offering innovative approaches to target and eradicate cancer cells at the genetic level. As of June 2024, the U.S. Food and Drug Administration (FDA) has approved several groundbreaking gene therapies, including those for various cancers, inherited eye conditions, and several blood disorders. Notably, eight of these FDA-approved gene therapies […]

2023 U.S. Granted Patents: Samsung maintains patent leadership

2023 U.S. Granted Patents: Samsung maintains patent leadership

According to our data, the USPTO granted a total of 345,344 patents in 2023 (FY 2023, spanning from October 1, 2022, to September 30, 2023). In this 2023 Patent Roundup series, we looked at patents granted by the USPTO in 2023 and analyzed the patenting trends of the top 10 assignees. Analyzing patent grants provides […]

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.

Disclaimer: 

1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership. 

2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.